Olivier Duclos

USPTO Granted Patents = 21 (Patent Applications = 4)

CIPO Patents = 4 (Patent Applications = 1)

EPO Patents = 14 (Patent Applications = 14)

Average Co-Inventor Count = 7.2

ph-index = 4

Forward Citations = 44(Granted Patents)

Location History:

Gentilly, FR (2015)
Paris, FR (2012 - 2023)

Company Filing History:

Years Active: 2012-2023

Loading Chart...

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11725036 - Modified lipidated relaxin B chain peptides and their therapeutic use (2023-08-15),

2. 10988524 - Modified relaxin B chain peptides and their therapeutic use (2021-04-27),

3. 10988523 - Modified lipidated Relaxin B chain peptides and their therapeutic use (2021-04-27),

4. 10980816 - Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof (2021-04-20),

5. 10961295 - Modified lipidated Relaxin B chain peptides and their therapeutic use (2021-03-30),

6. 10736904 - Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof (2020-08-11),

7. 10500212 - Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof (2019-12-10),

8. 10220044 - Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof (2019-03-05),

9. 9744176 - Therapeutic uses of novel thienopyrimidine derivatives (2017-08-29),

10. 9675606 - 2-amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors (2017-06-13),

11. 9169246 - Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof (2015-10-27),

12. 9126972 - 2-amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors (2015-09-08),

13. 9115140 - Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof (2015-08-25),

14. 8975250 - 5 oxo-5,8-dihydropyrido[2,3-d]pyrimidine derivatives as CaMKII kinase inhibitors for treating cardiovascular diseases (2015-03-10),

15. 8846712 - 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors (2014-09-30),

Title: Olivier Duclos: A Trailblazer in Biopharmaceutical Innovations

Introduction

Olivier Duclos, a distinguished inventor based in Paris, France, has made significant contributions to the field of biopharmaceuticals through his innovative work and patents. With an impressive portfolio of 21 patents, he is recognized for his pioneering research in peptide therapeutics and their potential medical applications.

Latest Patents

Among his recent inventions are two notable patents that focus on modified lipidated relaxin B chain peptides and their therapeutic use. The first patent describes a biologically active single-chain relaxin peptide with the formula N-Ac-L-E-G-R-E-K-V-R-A-X-I-X-X-E-G-X-S-T-F-S-X-R-A-X-NH-C. This innovative peptide formulation is aimed at therapeutic applications. The second patent presents a similar concept, detailing another single-chain relaxin peptide with the structure N-Ac-(E)-X-E-G-R-E-X-V-R-X-X-I-X-X-E-G-X-S-X-X-X-X-R-(X)-(X)-(K)-(X)-(gE)-X-C, along with its pharmaceutical composition, asserting its use as a medicament. These groundbreaking peptides hold promise for various therapeutic interventions.

Career Highlights

Olivier has worked with prominent companies in the pharmaceutical industry, including Sanofi and Sanofi-Aventis. His tenure at these organizations has allowed him to apply his innovative ideas and collaborate with some of the brightest minds in the field to advance research and development in drug therapies.

Collaborations

Throughout his career, Olivier has collaborated with esteemed colleagues such as Sergio Mallart and Maria Mendez-Perez. These partnerships have propelled his research further and facilitated the exchange of ideas that lead to groundbreaking advancements in peptide therapeutics.

Conclusion

Olivier Duclos stands out as an influential inventor in the biopharmaceutical arena. With 21 patents and a steadfast commitment to innovation, his work continues to shape the future of medicine, emphasizing the potential of peptide-based therapeutics. His contributions not only reflect his expertise but also inspire future advancements in the field.

This text is generated by artificial intelligence and may not be accurate.